Compare Regeneron Pharmaceuticals Inc (REGN) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Wynn Resorts, Limited — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while Wynn Resorts, Limited trades at $90.54 (market cap $9.50B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 8.8× Wynn Resorts, Limited's market cap, and Wynn Resorts, Limited pays the higher dividend (1.08%). Which is the better fit depends on your goals.
| REGN | WYNN | |
|---|---|---|
Market Cap | $83.43B | $9.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $852.03 | $133.34 |
52-Week Low | $555.51 | $90.23 |
Enterprise Value | $78.14B | $19.74B |
Dividend Yield | 0.46% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Wynn Resorts (WYNN) trades at $92.22, up 0.74% today, amid mixed technical signals with a bearish moving average trend but neutral oscillators. The company reported Q2 2026 EPS of $1.24, beating expectations, driven by Macau strength, though U.S. margins face pressure. Revenue reached $7.14B in 2025 with a net income margin of 4.58%, while debt remains elevated at $10.5B. Recent institutional buying includes Barrow Hanley's $321M investment, and analysts maintain a bullish consensus price target of $132.44.
Wynn's outlook is supported by Macau recovery and new project pipelines like Wynn Al Marjan, but high capital expenditure and debt load pose risks. The stock offers 44% upside to consensus target, though investors should monitor margin pressures and capex execution. Near-term support lies at $91, with resistance at $93.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
